{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:57:21Z","timestamp":1762181841303,"version":"build-2065373602"},"reference-count":61,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brain Sciences"],"abstract":"<jats:p>Background\/Objectives: Recent studies have identified some concerns related to the occurrence of eye disorders in offspring of opioid-prescribed mothers, and especially so in those exposed to methadone. The aim here was to investigate, from a pharmacovigilance point of view, the association between opioid exposure during pregnancy and reported eye disorders in children. Methods: The FDA Adverse Event Reporting System (FAERS) was searched for the following: reports of eye disorders in children aged 0\u201317 years exposed during pregnancy to either methadone or buprenorphine; top 20 medications administered during pregnancy and associated with eventual occurrence of eye disorders in children; and reports of eye disorders in children from mothers prescribed with a range of psychotropics. Results: For 190 methadone and 79 buprenorphine cases, occurrence of eye disorders was registered as the consequence of having been exposed to these drugs in utero. After data cleaning, residual cases for methadone and buprenorphine were 17 and 15, respectively. Overall, in comparing the odds of eye disorders given methadone exposure to the odds of eye disorders given buprenorphine exposure, which represents a relative Reporting Odds Ratio (ROR) between two drugs, the relative ROR between methadone and buprenorphine was 0.59, suggesting lower odds of eye disorders for methadone compared to buprenorphine in children 0\u201317 years old antenatally exposed to either methadone or buprenorphine. Conversely, the ROR values resulting from a comparison of methadone- or buprenorphine-related data versus all other psychotropic drugs resulted in 0.27 (95% CI 0.16\u20130.48) and 0.47 (95% CI 0.26\u20130.85), respectively, indicating lower reporting odds of eye disorders for these molecules versus the pooled non-opioid comparator group. Medications prescribed during pregnancy which were most frequently related to the occurrence of eye disorders included the following: dupilumab (126 reports), valproate (69 reports), and ibuprofen (52 reports). Indeed, no opiates\/opioids appeared among the top 20 drugs linked to eye disorders. A total of 25 and 11 unique cases were associated either with benzodiazepines or antipsychotics, respectively. Conclusions: No potential disproportionality safety signal for eye disorders associated with prenatal opioid exposure was identified. Specifically, the relative ROR indicated lower reporting odds for methadone compared to buprenorphine. The interpretation of these results is complicated by common co-exposures, polydrug interventions, and underlying maternal comorbidities, which introduce substantial confounding in real-world pharmacovigilance data. Overall, these findings highlight the importance of continued systematic post-marketing surveillance.<\/jats:p>","DOI":"10.3390\/brainsci15111177","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:23:59Z","timestamp":1761873839000},"page":"1177","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Possible Eye Disorders in Children Prenatally Exposed to Either Methadone or Buprenorphine in Comparison with Other Medications: An Examination of the Food and Drug Administration (FDA) Pharmacovigilance Database"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6810-1540","authenticated-orcid":false,"given":"Stefania","family":"Chiappini","sequence":"first","affiliation":[{"name":"School of Medicine, UniCamillus University, Via di S. Alessandro 8, 00131 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6882-3770","authenticated-orcid":false,"given":"Laura","family":"Orsolini","sequence":"additional","affiliation":[{"name":"Unit of Clinical Psychiatry, Department of Experimental and Clinical Medicine (DIMSC), Faculty of Medicine and Surgery, Polytechnic University of Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-817X","authenticated-orcid":false,"given":"John Martin","family":"Corkery","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, Hertfordshire Medical School, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8255-0660","authenticated-orcid":false,"given":"Amira","family":"Guirguis","sequence":"additional","affiliation":[{"name":"Pharmacy, Medical School, Swansea University, Swansea SA2 8PP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3832-1398","authenticated-orcid":false,"given":"Alessio","family":"Mosca","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. D\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8843-0595","authenticated-orcid":false,"given":"Davide","family":"Arillotta","sequence":"additional","affiliation":[{"name":"Department of Neurosciences, Psychology, Drug Research, and Child Health, Section of Pharmacology and Toxicology, University of Florence, 50121 Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2341","authenticated-orcid":false,"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. D\u2019Annunzio\u201d University, 66100 Chieti, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4178-5401","authenticated-orcid":false,"given":"Fabrizio","family":"Schifano","sequence":"additional","affiliation":[{"name":"Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, Hertfordshire Medical School, University of Hertfordshire, Hatfield AL10 9AB, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/AOG.0000000000002579","article-title":"Prescription and Other Medication Use in Pregnancy","volume":"131","author":"Haas","year":"2018","journal-title":"Obstet. Gynecol."},{"unstructured":"World Health Organization (WHO) (2025, September 16). Breastfeeding and Maternal Medication. Recommendations for Drugs in the Eleventh WHO Model List of Essential Drugs. Available online: https:\/\/www.who.int\/publications\/i\/item\/55732.","key":"ref_2"},{"unstructured":"CDC (2025, September 25). Treatment of Opioid Use Disorder Before, During, and After Pregnancy, Available online: https:\/\/www.cdc.gov\/opioid-use-during-pregnancy\/treatment\/index.html.","key":"ref_3"},{"unstructured":"American College of Obstetricians and Gynecologists (ACOG) (2025, September 25). Opioid Use and Opioid Use Disorder in Pregnancy Committee Opinion Number 711 (August 2017). Available online: https:\/\/www.acog.org\/clinical\/clinical-guidance\/committee-opinion\/articles\/2017\/08\/opioid-use-and-opioid-use-disorder-in-pregnancy.","key":"ref_4"},{"unstructured":"CRAT\u2014Reference Center for Teratogenic Agents (2025, September 25). Buprenorphine\u2014Pregnancy. Available online: https:\/\/www.lecrat.fr\/12748.","key":"ref_5"},{"unstructured":"CRAT\u2014Reference Center for Teratogenic Agents (2025, September 25). Methadone\u2014Pregnancy. Available online: https:\/\/www.lecrat.fr\/12738\/.","key":"ref_6"},{"unstructured":"UK Teratology Information Service (UKTIS) (2025, September 25). Use of Buprenorphine in Pregnancy. Available online: https:\/\/uktis.org\/monographs\/use-of-buprenorphine-in-pregnancy\/.","key":"ref_7"},{"unstructured":"UK Teratology Information Service (UKTIS) (2025, September 25). USE OF HEROIN IN PREGNANCY. Available online: https:\/\/uktis.org\/monographs\/use-of-heroin-in-pregnancy\/.","key":"ref_8"},{"doi-asserted-by":"crossref","unstructured":"(2020). The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J. Addict. Med., 14, 1\u201391.","key":"ref_9","DOI":"10.1097\/ADM.0000000000000633"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105188","DOI":"10.1016\/j.earlhumdev.2020.105188","article-title":"Prenatal opioid exposure\u2014Increasing evidence of harm","volume":"150","author":"Mactier","year":"2020","journal-title":"Early Hum. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/aos.15764","article-title":"Visual function in Norwegian children aged 5\u201313\u2009years with prenatal exposure to opioid maintenance therapy: A case-control study","volume":"102","author":"Aslaksen","year":"2024","journal-title":"Acta Ophthalmol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41433-023-02644-3","article-title":"Impaired vision in children prenatally exposed to methadone: An observational cohort study","volume":"38","author":"Hamilton","year":"2024","journal-title":"Eye"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104601","DOI":"10.1016\/j.neubiorev.2022.104601","article-title":"Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: A systematic review and meta-analysis","volume":"136","author":"Hemmati","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1545968311407780","article-title":"Greater sparing of visual search abilities in children after congenital rather than acquired focal brain damage","volume":"25","author":"Tinelli","year":"2011","journal-title":"Neurorehabil. Neural Repair"},{"key":"ref_15","first-page":"104259","article-title":"Instrument-based vision screening and outcomes in young children following prenatal exposure to buprenorphine or methadone: A retrospective cohort study","volume":"29","author":"Bush","year":"2025","journal-title":"J. AAPOS Off. Publ. Am. Assoc. Pediatr. Ophthalmol. Strabismus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/bjo.2009.169284","article-title":"Ophthalmic, clinical and visual electrophysiological findings in children born to mothers prescribed substitute methadone in pregnancy","volume":"94","author":"Hamilton","year":"2010","journal-title":"Br. J. Ophthalmol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1360-0443.2012.04006.x","article-title":"Neurodevelopmental investigation of the mirror neurone system in children of women receiving opioid maintenance therapy during pregnancy","volume":"108","author":"Konijnenberg","year":"2013","journal-title":"Addiction"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/bjophthalmol-2013-303967","article-title":"Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy","volume":"98","author":"McGlone","year":"2014","journal-title":"Br. J. Ophthalmol."},{"unstructured":"European Medicines Agency (2025, September 16). PRAC Strategy on Measuring the Impact of Pharmacovigilance Activities (Revision 2). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/prac-strategy-measuring-impact-pharmacovigilance-activities_en.pdf.","key":"ref_19"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/2042098617736422","article-title":"The hope, hype and reality of Big Data for pharmacovigilance","volume":"9","author":"Bate","year":"2018","journal-title":"Ther. Adv. Drug Saf."},{"doi-asserted-by":"crossref","unstructured":"Schifano, F., and Chiappini, S. (2018). Is there such a thing as a \u2018lope\u2019 dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. PLoS ONE, 13.","key":"ref_21","DOI":"10.1371\/journal.pone.0204443"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40263-016-0359-y","article-title":"A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency\u2019s \u2018Suspected Adverse Drug Reactions\u2019 Database","volume":"30","author":"Chiappini","year":"2016","journal-title":"CNS Drugs"},{"unstructured":"Food and Drug Administration (2025, September 16). FDA In Brief: FDA Approves New Packaging for Brand-Name Over-the-Counter Loperamide to Help Curb Abuse and Misuse, Available online: https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-approves-new-packaging-brand-name-over-counter-loperamide-help-curb-abuse-and-misuse.","key":"ref_23"},{"unstructured":"GOV.UK (2025, September 16). \n            Pregabalin (Lyrica), Gabapentin (Neurontin) and Risk of Abuse and Dependence: New Scheduling Requirements from 1 April\n          , Available online: https:\/\/www.gov.uk\/drug-safety-update\/pregabalin-lyrica-gabapentin-neurontin-and-risk-of-abuse-and-dependence-new-scheduling-requirements-from-1-april.","key":"ref_24"},{"doi-asserted-by":"crossref","unstructured":"Baldini, S., Khattak, A., Capogrosso, P., Antonini, G., Deh\u00f2, F., Schifano, F., and Schifano, N. (2023). The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database. Brain Sci., 13.","key":"ref_25","DOI":"10.3390\/brainsci13121652"},{"doi-asserted-by":"crossref","unstructured":"Spowart, K.M., Reilly, K., Mactier, H., and Hamilton, R. (2023). Executive functioning, behavioural, emotional, and cognitive difficulties in school-aged children prenatally exposed to methadone. Front. Pediatr., 11.","key":"ref_26","DOI":"10.3389\/fped.2023.1118634"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/pds.2184","article-title":"Prescription drug use during pregnancy in developed countries: A systematic review","volume":"20","author":"Daw","year":"2011","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/pds.4213","article-title":"Safety profile of medication used during pregnancy: Results of a multinational European study","volume":"26","author":"Lupattelli","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/ICU.0b013e3283654db2","article-title":"Ocular manifestations of drug and alcohol abuse","volume":"24","author":"Peragallo","year":"2013","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/apa.12210","article-title":"Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy","volume":"102","author":"Sarman","year":"2013","journal-title":"Acta Paediatr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drugalcdep.2017.11.030","article-title":"Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes","volume":"185","author":"Kaltenbach","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41380-024-02697-0","article-title":"Safety of psychotropic medications in pregnancy: An umbrella review","volume":"30","author":"Fabiano","year":"2025","journal-title":"Mol. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1176\/appi.ajp.2017.16091006","article-title":"The Protective Effect of Pregnancy on Risk for Drug Abuse: A Population, Co-Relative, Co-Spouse, and Within-Individual Analysis","volume":"174","author":"Kendler","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00737-022-01244-6","article-title":"Licit and illicit drug use across trimesters in pregnant women endorsing past-year substance use: Results from National Survey on Drug Use and Health (2009\u20132019)","volume":"25","author":"Peltier","year":"2022","journal-title":"Arch. Women\u2019s Ment. Health"},{"doi-asserted-by":"crossref","unstructured":"Dubucs, C., Plaisanci\u00e9, J., Courtade-Saidi, M., and Damase-Michel, C. (2024). The first review on prenatal drug exposure and ocular malformation occurrence. Front. Pediatr., 12.","key":"ref_35","DOI":"10.3389\/fped.2024.1379875"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"J. Neurosci. Rural Pract."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1056\/NEJMoa2203318","article-title":"Buprenorphine versus Methadone for Opioid Use Disorder in Pregnancy","volume":"387","author":"Suarez","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/bjo.2006.105569","article-title":"Nystagmus secondary to drug exposure in utero","volume":"91","author":"Mulvihill","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.52504\/001c.16759","article-title":"The Effects of Opioids During Pregnancy: A Literature Review","volume":"4","author":"Asdjodi","year":"2020","journal-title":"Georget. Med. Rev."},{"doi-asserted-by":"crossref","unstructured":"Cleymaet, A., Berezin, C., and Vigh, J. (2015). Endogenous Opioid Signaling in the Mouse Retina Modulates Pupillary Light Reflex. Int. J. Mol. Sci., 22.","key":"ref_41","DOI":"10.3390\/ijms22020554"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0024-3205(83)90123-6","article-title":"The pupillary effects of opioids","volume":"33","author":"Murray","year":"1983","journal-title":"Life Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.clinph.2008.01.106","article-title":"Mechanism of opioid-induced pupillary effects","volume":"119","author":"Larson","year":"2008","journal-title":"Clin. Neurophysiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1097\/ALN.0000000000000384","article-title":"Pupillary Effects of High-dose Opioid Quantified with Infrared Pupillometry","volume":"121","author":"Rollins","year":"2014","journal-title":"Anesthesiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100996","DOI":"10.1016\/j.dcn.2021.100996","article-title":"Effects of prenatal opioid exposure on functional networks in infancy","volume":"51","author":"Merhar","year":"2021","journal-title":"Dev. Cogn. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and Exogenous Opioids in Pain","volume":"41","author":"Corder","year":"2018","journal-title":"Annu. Rev. Neurosci."},{"doi-asserted-by":"crossref","unstructured":"Swingler, M., Donadoni, M., Unterwald, E., Maggirwar, S., and Sariyer, I. (2025). Molecular and cellular basis of mu-opioid receptor signaling: Mechanisms underlying tolerance and dependence development. Front. Neurosci., 19.","key":"ref_47","DOI":"10.3389\/fnins.2025.1597922"},{"doi-asserted-by":"crossref","unstructured":"Reeves, K., Shah, N., Mu\u00f1oz, B., and Atwood, B. (2022). Opioid Receptor-Mediated Regulation of Neurotransmission in the Brain. Front. Mol. Neurosci., 15.","key":"ref_48","DOI":"10.3389\/fnmol.2022.919773"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.2174\/138161212803582441","article-title":"Non-analgesic effects of opioids: Neuroprotection in the retina","volume":"18","author":"Husain","year":"2012","journal-title":"Curr. Pharm. Des."},{"doi-asserted-by":"crossref","unstructured":"Paul, A.K., Smith, C.M., Rahmatullah, M., Nissapatorn, V., Wilairatana, P., Spetea, M., Gueven, N., and Dietis, N. (2021). Opioid Analgesia and Opioid-Induced Adverse Effects: A Review. Pharmaceuticals, 14.","key":"ref_50","DOI":"10.3390\/ph14111091"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0895-4356(02)00450-X","article-title":"Physicians\u2019 knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions","volume":"55","author":"Hasford","year":"2002","journal-title":"J. Clin. Epidemiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-0716-4003-6_16","article-title":"Investigating the Benefit-Risk Profile of Drugs: From Spontaneous Reporting Systems to Real-World Data for Pharmacovigilance","volume":"2834","author":"Imbrici","year":"2025","journal-title":"Methods Mol. Biol."},{"unstructured":"European Medicines Agency (2025, September 16). Guide on the Interpretation of Spontaneous Case Reports of Suspected Adverse Reactions to Medicines. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/report\/guide-interpretation-spontaneous-case-reports-suspected-adverse-reactions-medicines_en.pdf.","key":"ref_53"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0043-1771388","article-title":"Long-Term Visual and Neurodevelopmental Outcomes in Two Children with Congenital Nystagmus Secondary to Methadone Exposure In utero","volume":"54","author":"Galli","year":"2023","journal-title":"Neuropediatrics"},{"unstructured":"(2025, September 25). MotherToBaby|Fact Sheets [Internet]; Organization of Teratology Information Specialists (OTIS): Brentwood, TN, USA, 2025; Buprenorphine (Buprenex\u00ae), Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582609\/.","key":"ref_55"},{"unstructured":"(2025, September 25). MotherToBaby|Fact Sheets [Internet]; Organization of Teratology Information Specialists (OTIS): Brentwood, TN, USA, 2023; Methadone, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK582830\/.","key":"ref_56"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e20190128","DOI":"10.1542\/peds.2019-0128","article-title":"Prenatal Opioid Exposure: Neurodevelopmental Consequences and Future Research Priorities","volume":"144","author":"Conradt","year":"2019","journal-title":"Pediatrics"},{"unstructured":"Anbalagan, S., Falkowitz, D.M., and Mendez, M.D. (2025, September 27). Neonatal Abstinence Syndrome. [Updated 1 April 2024], StatPearls [Internet], Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551498\/.","key":"ref_58"},{"unstructured":"CDC (2025, September 27). Treat and Manage Infants Affected by Prenatal Opioid Exposure, Available online: https:\/\/www.cdc.gov\/opioid-use-during-pregnancy\/treatment\/infants-opioid.html?utm_source=chatgpt.com%20%22Treat%20and%20Manage%20Infants%20Affected%20by%20Prenatal%20Opioid%20...%22.","key":"ref_59"},{"doi-asserted-by":"crossref","unstructured":"Yen, E., and Davis, J.M. (2022). The immediate and long-term effects of prenatal opioid exposure. Front. Pediatr., 10.","key":"ref_60","DOI":"10.3389\/fped.2022.1039055"},{"unstructured":"European Medicines Agency (2025, September 16). Guideline on the Exposure to Medicinal Products During Pregnancy: Need for Post-Authorisation Data. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-exposure-medicinal-products-during-pregnancy-need-post-authorisation-data_en.pdf.","key":"ref_61"}],"container-title":["Brain Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/11\/1177\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:05:58Z","timestamp":1762178758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-3425\/15\/11\/1177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":61,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["brainsci15111177"],"URL":"https:\/\/doi.org\/10.3390\/brainsci15111177","relation":{},"ISSN":["2076-3425"],"issn-type":[{"type":"electronic","value":"2076-3425"}],"subject":[],"published":{"date-parts":[[2025,10,30]]}}}